RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
Rhea-AI Summary
RenovoRx (Nasdaq: RNXT) will present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20, 2026. CEO Shaun Bagai and CFO Mark Voll will discuss record Q1 2026 RenovoCath revenue, device adoption, repeat orders, and key clinical programs.
They will review the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, expected enrollment completion by end of June 2026 and final data mid to late 2027, plus investigator-initiated and registry studies.
Positive
- None.
Negative
- None.
News Market Reaction – RNXT
In the May 19 session, RNXT gained 2.90%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Earnings results | Positive | -4.1% | Record Q1 2026 revenue and expanded cancer center adoption reported. |
| Apr 29 | Earnings call notice | Positive | -1.1% | Announcement of Q1 2026 results and business highlights conference call. |
| Apr 23 | ASCO abstract | Positive | -5.1% | TIGeR‑PaC pharmacokinetic and pharmacodynamic sub‑study accepted for ASCO. |
| Apr 14 | Clinical data | Positive | +1.0% | Clinical imaging data for TAMP platform presented at 2026 SIR meeting. |
| Apr 08 | Patent allowance | Positive | +4.3% | First Japanese patent notice of allowance for RenovoCath and TAMP platform. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational and clinical headlines have often met selling pressure, though some IP and data milestones have aligned with gains.
Over the last several months, RenovoRx has highlighted multiple milestones: IP strengthening via a Japanese patent allowance, clinical imaging data for its TAMP platform at the 2026 SIR meeting, and ASCO abstract acceptance for TIGeR‑PaC. It then guided to nearing full enrollment and reported record Q1 2026 revenue of $563,000 with expanded cancer-center adoption. Despite these fundamentally constructive updates, several past news days (including the record quarter and ASCO abstract) coincided with negative price reactions, framing today’s conference appearance within a pattern of mixed trading responses to positive news.
Key Terms
fda-cleared regulatory
drug-delivery device medical
phase iii medical
clinical trial medical
intra-arterial medical
investigator-initiated trials medical
post-marketing registry studies medical
therapy platform medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai and Chief Financial Officer Mark Voll will participate in the Alliance Global Partners (AGP) Annual Healthcare Company Showcase, hosted by Scott Henry, AGP’s Managing Director and Senior Healthcare Analyst, on May 20, 2026.
Mr. Bagai and Mr. Voll will discuss RenovoRx’s commercial progress, including record first-quarter 2026 revenue from RenovoCath as a standalone drug-delivery device, accelerating RenovoCath adoption at high-volume cancer centers, and growing repeat orders. They will also highlight the Company’s clinical research programs, including the ongoing Phase III TIGeR-PaC clinical trial evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, (known as IAG)) in locally advanced pancreatic cancer (“LAPC”). RenovoRx expects to send notification of closure of enrollment in the trial in the beginning of June, completing the Company's milestone of finishing trial enrollment by the end of June 2026. The Company continues to anticipate final data in mid to late 2027.
Additionally, Mr. Bagai and Mr. Voll will outline RenovoRx’s ongoing support for investigator-initiated trials (IITs) in borderline resectable and metastatic pancreatic cancer, as well as post-marketing registry studies. Registry and IIT studies are capital-efficient studies providing meaningful data that may further broaden the application for the TAMP therapy platform which is enabled by RenovoCath.
AGP Virtual Annual Healthcare Company Showcase Details:
Date: Wednesday, May 20, 2026
Time: 1:40 PM ET
Speakers: Shaun Bagai, CEO and Mark Voll, CFO
Moderator: Scott Henry, AGP’s, Managing Director and Senior Healthcare Analyst
Webcast: https://ir.renovorx.com/news-events/ir-calendar-events
To schedule a one-on-one investor meeting with RenovoRx’s management team, please contact KCSA Strategic Communications at renovorx@kcsa.com. A replay of the webcast will be available for 30 days at https://ir.renovorx.com/news-events/ir-calendar-events.
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately
RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx anticipates full enrollment in the TIGeR-PaC trial in June 2026 and final data readout in mid to late 2027.
The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release, the presentation described herein, and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies (including expectations for full enrollment and data read out), (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” "aim," "goal," “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xvii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at https://ir.renovorx.com/sec-filings.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Investor Relations Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@KCSA.com
Media Contact:
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com
